Illustration of misfolded prion proteins in the brain.

Prion Diseases: Unraveling the Mystery of Misfolded Proteins

Avery Sinclair in Health & Wellness December 2025 • 4 min read.

"Exploring the causes, symptoms, and potential treatments for prion diseases, a class of rare and devastating neurological disorders."

Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a group of rare and fatal neurodegenerative disorders. What makes these diseases unique is that they are caused by prions – misfolded proteins that can induce normal proteins to misfold in a similar way. This chain reaction leads to the accumulation of abnormal proteins in the brain, causing severe damage.

Unlike diseases caused by viruses or bacteria, prion diseases are associated with infectious, inherited, and spontaneous origins, making them a complex and challenging area of research. The "protein-only" hypothesis suggests that the conversion of a normal prion protein (PrPC) into an aggregated scrapie form (PrPSc) is the primary cause of TSEs. This PrPSc accumulates and inflicts damage, leading to the diseases' characteristic symptoms.

These diseases manifest in various forms, including Creutzfeldt-Jakob disease (CJD), fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and kuru in humans, as well as bovine spongiform encephalopathy (BSE) in cattle and scrapie in sheep. Each of these conditions presents unique challenges and symptoms, but they all share the underlying mechanism of prion-induced protein misfolding.

Understanding the Structure and Function of Prion Proteins

Illustration of misfolded prion proteins in the brain.

The human prion protein, denoted as PrP, is a glycoprotein encoded by the PrP gene. This gene resides on the short arm of chromosome 20. PrP exists in two primary isoforms: PrPC (cellular) and PrPSc (scrapie). While both isoforms share an identical chemical composition, their three-dimensional conformations differ significantly. This structural divergence is key to understanding prion diseases.

PrPC, the normal form, is characterized by a flexible structure consisting of alpha helices. Key features of PrPC include:

It's a transmembrane glycoprotein typically found on the surface of cells, particularly neural and hematopoietic stem cells.
Its secondary structure is dominated by alpha helices, likely three in number, contributing to its flexible and soluble nature.
PrPC is easily soluble and readily digested by proteases, enzymes that break down proteins.
Encoded by the PRNP gene on chromosome 20, PrPC may function as an acetyl-choline receptor inducer, playing a crucial role in nerve signal transmission.

In contrast, PrPSc, the aberrant form, undergoes a conformational change where some alpha helices stretch out into flat structures known as beta strands. Notable characteristics of PrPSc include:

The Future of Prion Disease Research

Although prion diseases remain a significant challenge, ongoing research efforts offer hope for future treatments. Scientists are exploring various strategies, including developing drugs that can prevent the misfolding of prion proteins, therapies that target and clear existing prions, and gene therapies that could correct the underlying genetic mutations. By continuing to unravel the mysteries of prion diseases, researchers aim to develop effective therapies that can improve the lives of those affected by these devastating conditions.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What exactly are prion diseases and what makes them so unique compared to other types of diseases?

Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are rare and fatal neurodegenerative disorders. They are unique because they're caused by prions, which are misfolded proteins that can induce normal proteins to misfold similarly, leading to the accumulation of abnormal proteins in the brain and causing severe damage. Unlike diseases caused by viruses or bacteria, prion diseases can have infectious, inherited, and spontaneous origins. This complexity makes them a challenging area of research, particularly due to the 'protein-only' hypothesis, which suggests that the conversion of a normal prion protein (PrPC) into an aggregated scrapie form (PrPSc) is the primary cause of TSEs.

How does the normal prion protein (PrPC) differ in structure and function from the misfolded prion protein (PrPSc), and why is this difference so critical?

The normal prion protein (PrPC) and the misfolded prion protein (PrPSc) share the same chemical composition but have distinct three-dimensional conformations. PrPC is characterized by a flexible structure consisting of alpha helices. It's a transmembrane glycoprotein typically found on the surface of cells, especially neural and hematopoietic stem cells. PrPC is soluble and easily digested by proteases. In contrast, PrPSc undergoes a conformational change where some alpha helices stretch out into flat structures known as beta strands. This structural change makes PrPSc resistant to degradation by proteases and causes it to accumulate in the brain, leading to neuronal damage. This structural divergence is key because the conversion from PrPC to PrPSc is the central event in the pathogenesis of prion diseases.

What are some of the different types of prion diseases in humans and animals, and how do they manifest?

Prion diseases manifest in various forms in both humans and animals. In humans, examples include Creutzfeldt-Jakob disease (CJD), fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and kuru. Each of these conditions presents unique symptoms and challenges, but they all share the underlying mechanism of prion-induced protein misfolding. In animals, notable prion diseases include bovine spongiform encephalopathy (BSE) in cattle and scrapie in sheep. These diseases typically cause neurological damage, leading to symptoms such as cognitive decline, motor dysfunction, and eventually death. The specific symptoms and progression can vary depending on the type of prion disease and the species affected.

What are the current research directions being explored to potentially treat or prevent prion diseases, and what challenges do researchers face?

Current research efforts are exploring various strategies to treat or prevent prion diseases. These include developing drugs that can prevent the misfolding of prion proteins, therapies that target and clear existing prions, and gene therapies that could correct the underlying genetic mutations. One significant challenge researchers face is the difficulty in developing drugs that can specifically target PrPSc without affecting PrPC, as both proteins share similar structures. Additionally, the rarity and slow progression of prion diseases make it challenging to conduct clinical trials and assess the effectiveness of potential treatments.

Given that PrPC may function as an acetyl-choline receptor inducer, what are the potential implications if PrPSc disrupts this function, and how might this contribute to the symptoms of prion diseases?

If PrPC functions as an acetyl-choline receptor inducer, its disruption by PrPSc could have significant implications for nerve signal transmission. Acetylcholine is a crucial neurotransmitter involved in various cognitive and motor functions, so any disruption could lead to neurological symptoms. When PrPSc accumulates and interferes with the normal function of PrPC, it may impair the induction of acetylcholine receptors, leading to deficits in cholinergic neurotransmission. This could contribute to symptoms such as cognitive decline, motor dysfunction, and behavioral changes seen in prion diseases. Understanding this mechanism could provide insights into developing targeted therapies to mitigate these specific neurological deficits.